Gene therapy approaches for lysosomal storage disease: Next-generation treatment

Human Gene Therapy

Volumn 23, Issue 8, 2012, Pages 808-815

  Byrne, Barry J ^a,b   Falk, Darin J ^a,b   Clément, Nathalie ^a,b   Mah, Cathryn S ^a,b  

^a Department of Pediatrics ^*  (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGALSIDASE ALFA; AGALSIDASE BETA; GALSULFASE; IDURONATE 2 SULFATASE; IMIGLUCERASE; LARONIDASE; MIGLUSTAT; TALIGLUCERASE ALFA; VELAGLUCERASE ALFA; VIRUS VECTOR;

ARTICLE; ENZYME REPLACEMENT; FABRY DISEASE; GAUCHER DISEASE; GENE THERAPY; GLYCOGEN STORAGE DISEASE TYPE 2; HUNTER SYNDROME; HURLER SYNDROME; LYSOSOME STORAGE DISEASE; MAROTEAUX LAMY SYNDROME; METACHROMATIC LEUKODYSTROPHY; MORQUIO SYNDROME; NEURONAL CEROID LIPOFUSCINOSIS; NIEMANN PICK DISEASE; NONHUMAN;

ANIMALS; CLINICAL TRIALS AS TOPIC; ENZYME REPLACEMENT THERAPY; GENETIC THERAPY; GENETIC VECTORS; HUMANS; LYSOSOMAL STORAGE DISEASES;

EID: 84865226367     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.140     Document Type: Article

References (72)

1. Alexander, B.L., Ali, R.R., Alton, E.W., et al. (2007). Progress and prospects: Gene therapy clinical trials (part 1). Gene Ther. 14, 1439-1447.
2. Arruda, V.R., Favaro, P., and Finn, J.D. (2009). Strategies to modulate immune responses: A new frontier for gene therapy. Mol. Ther. 17, 1492-1503.
3. Bevan, A.K., Duque, S., Foust, K.D., et al. (2011). Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol. Ther. 19, 1971-1980.
4. Bielicki, J., McIntyre, C., and Anson, D.S. (2010). Comparison of ventricular and intravenous lentiviral-mediated gene therapy for murine MPS VII. Mol. Genet. Metab. 101, 370-382.
5. Biffi, A., and Naldini, L. (2005). Gene therapy of storage disorders by retroviral and lentiviral vectors. Hum. Gene Ther. 16, 1133-1142.
6. Brooks, D.A., Kakavanos, R., and Hopwood, J.J. (2003). Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol. Med. 9, 450-453.
7. Byrne, B., Smith, B., Martin, A., et al. (2012). Phase I/II trial of adeno-associated virus acid-a-glucosidase (AAV-GAA) diaphragm gene therapy for ventilatory failure in Pompe disease. Mol. Genet. Metab. 105, S24.
8. Byrne, B.J., Falk, D.J., Pacak, C.A., et al. (2011). Pompe disease gene therapy. Hum. Mol. Genet. 20, R61-R68.
9. Cabrera-Salazar, M.A., Roskelley, E.M., Bu, J., et al. (2007). Timing of therapeutic intervention determines functional and survival outcomes in a mouse model of late infantile Batten disease. Mol. Ther. 15, 1782-1788.
10. Cardone, M., Porto, C., Tarallo, A., et al. (2008). Abnormal mannose-6-phosphate receptor trafficking impairs recombinant a-glucosidase uptake in Pompe disease fibroblasts. Pathogenetics 1, 6.
11. Cotugno, G., Annunziata, P., Tessitore, A., et al. (2011). Longterm amelioration of feline mucopolysaccharidosis VI after AAV-mediated liver gene transfer. Mol. Ther. 19, 461-469.
12. Cresawn, K.O., Fraites, T.J., Wasserfall, C., et al. (2005). Impact of humoral immune response on distribution and efficacy of recombinant adeno-associated virus-derived acid a-glucosidase in a model of glycogen storage disease type II. Hum. Gene Ther. 16, 68-80.
13. Dayton, R.D., Wang, D.B., and Klein, R.L. (2012). The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin. Biol. Ther. 12, 757-766.
14. DeRuisseau, L.R., Fuller, D.D., Qiu, K., et al. (2009). Neural deficits contribute to respiratory insufficiency in Pompe disease. Proc. Natl. Acad. Sci. U.S.A. 106, 9419-9424.
15. Di Domenico, C., Villani, G.R., Di Napoli, D., et al. (2009). In-tracranial gene delivery of LV-NAGLU vector corrects neu-ropathology in murine MPS IIIB. Am. J. Med. Genet. A 149A, 1209-1218.
16. Dimattia, M.A., Nam, H.J., Van Vliet, K., et al. (2012). Structural insight into the unique properties of adeno-associated virus serotype 9. J. Virol. 86, 6947-6958.
17. + cells from patients with Gaucher disease: In vivo detection of transduced cells without myeloablation. Hum. Gene Ther. 9, 2629-2640.
18. Ellinwood, N.M., Vite, C.H., and Haskins, M.E. (2004). Gene therapy for lysosomal storage diseases: The lessons and promise of animal models. J. Gene Med. 6, 481-506.
19. Ellinwood, N.M., Ausseil, J., Desmaris, N., et al. (2011). Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol. Ther. 19, 251-259.
20. ElMallah, M.K., Falk, D., Lane, M., et al. (2012). Retrograde gene delivery to hypoglossal motoneurons using AAV9. Hum. Gene Ther. Methods (in press).
21. Eto, Y., Shen, J.S., Meng, X.L., and Ohashi, T. (2004). Treatment of lysosomal storage disorders: Cell therapy and gene therapy. J. Inherit. Metab. Dis. 27, 411-415.
22. Falk, D., Soustek, M.S., Mah, C.S., et al. (2011). Next generation treatment of Pompe disease using systemic gene transfer with AAV9. Mol. Genet. Metab. 102, S18.
23. Foust, K.D., Nurre, E., Montgomery, C.L., et al. (2009). In-travascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 27, 59-65.
24. Fu, H.Y., Dirosario, J., Killedar, S., et al. (2011). Correction of neurological disease of mucopolysaccharidosis IIIB in adult mice by rAAV9 trans-blood-brain barrier gene delivery. Mol. Ther. 19, 1025-1033.
25. Gao, G., Vandenberghe, L.H., and Wilson, J.M. (2005). New recombinant serotypes of AAV vectors. Curr. Gene Ther. 5, 285-297.
26. Gao, G., Zhong, L., and Danos, O. (2011). Exploiting natural diversity of AAV for the design of vectors with novel properties. Methods Mol. Biol. 807, 93-118.
27. Hodges, B.L., and Cheng, S.H. (2006). Cell and gene-based therapies for the lysosomal storage diseases. Curr. Gene Ther. 6, 227-241.
28. Hsich, G., Sena-Esteves, M., and Breakefield, X.O. (2002). Critical issues in gene therapy for neurologic disease. Hum. Gene Ther. 13, 579-604.
29. Kamata, Y., Tanabe, A., Kanaji, A., et al. (2003). Long-term normalization in the central nervous system, ocular manifestations, and skeletal deformities by a single systemic adeno-virus injection into neonatal mice with mucopolysaccharidosis VII. Gene Ther. 10, 406-414.
30. Kiang, A., Hartman, Z.C., Liao, S., et al. (2006). Fully deleted adenovirus persistently expressing GAA accomplishes longterm skeletal muscle glycogen correction in tolerant and nontolerant GSD-II mice. Mol. Ther. 13, 127-134.
31. Koeberl, D.D., Kishnani, P.S., and Chen, Y.T. (2007). Glycogen storage disease types I and II: Treatment updates. J. Inherit. Metab. Dis. 30, 159-164.
32. Kosuga, M., Takahashi, S., Sasaki, K., et al. (2000). Adenovirus-mediated gene therapy for mucopolysaccharidosis VII: Involvement of cross-correction in wide-spread distribution of the gene products and long-term effects of CTLA-4Ig coex-pression. Mol. Ther. 1, 406-413.
33. Lau, A.A., Rozaklis, T., Ibanes, S., et al. (2012). Helper-dependent canine adenovirus vector-mediated transgene expression in a neurodegenerative lysosomal storage disorder. Gene 491, 53-57.
34. Lee, K.Z., Qiu, K., Sandhu, M.S., et al. (2011). Hypoglossal neu-ropathology and respiratory activity in Pompe mice. Front. Physiol. 2, 31.
35. Liu, Y., Xu, L., Hennig, A.K., et al. (2005). Liver-directed neonatal gene therapy prevents cardiac, bone, ear, and eye disease in mucopolysaccharidosis I mice. Mol. Ther. 11, 35-47.
36. LoDuca, P.A., Hoffman, B.E., and Herzog, R.W. (2009). Hepatic gene transfer as a means of tolerance induction to transgene products. Curr. Gene Ther. 9, 104-114.
37. Macsai, C.E., Derrick-Roberts, A.L., Ding, X., et al. (2012). Skeletal response to lentiviral mediated gene therapy in a mouse model of MPS VII. Mol. Genet. Metab. 106, 202-213.
38. Mah, C., Byrne, B.J., and Flotte, T.R. (2002). Virus-based gene delivery systems. Clin. Pharmacokinet. 41, 901-911.
39. Mah, C., Fraites, T.J., Jr., Cresawn, K.O., et al. (2004). A new method for recombinant adeno-associated virus vector delivery to murine diaphragm. Mol. Ther. 9, 458-463.
40. Mah, C., Pacak, C.A., Cresawn, K.O., et al. (2007). Physiological correction of Pompe disease by systemic delivery of adeno-associated virus serotype 1 vectors. Mol. Ther. 15, 501-507.
41. Mah, C.S., Falk, D.J., Germain, S.A., et al. (2010). Gel-mediated delivery of AAV1 vectors corrects ventilatory function in Pompe mice with established disease. Mol. Ther. 18, 502-510.
42. Mays, L.E., and Wilson, J.M. (2011). The complex and evolving story of T cell activation to AAV vector-encoded transgene products. Mol. Ther. 19, 16-27.
43. McKay, T.R., Rahim, A.A., Buckley, S.M., et al. (2011). Perinatal gene transfer to the liver. Curr. Pharm. Des. 17, 2528-2541.
44. Meikle, P.J., and Hopwood, J.J. (2003). Lysosomal storage disorders: Emerging therapeutic options require early diagnosis. Eur. J. Pediatr. 162(Suppl. 1), S34-S37.
45. Mingozzi, F., and High, K.A. (2011). Immune responses to AAV in clinical trials. Curr. Gene Ther. 11, 321-330.
46. Nakamura, K., Hattori, K., and Endo, F. (2011). Newborn screening for lysosomal storage disorders. Am. J. Med. Genet. C Semin. Med. Genet. 157, 63-71.
47. Naldini, L. (2011). Ex vivo gene transfer and correction for cell-based therapies. Nat. Rev. Genet. 12, 301-315.
48. Nayak, S., and Herzog, R.W. (2010). Progress and prospects: Immune responses to viral vectors. Gene Ther. 17, 295-304.
49. Nayak, S., Cao, O., Hoffman, B.E., et al. (2009). Prophylactic immune tolerance induced by changing the ratio of antigen-specific effector to regulatory T cells. J. Thromb. Haemost. 7, 1523-1532.
50. Pacak, C.A., Mah, C.S., Thattaliyath, B.D., et al. (2006). Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ. Res. 99, e3-e9.
51. Ponder, K.P. (2007). Immunology of neonatal gene transfer. Curr. Gene Ther. 7, 403-410.
52. Ponder, K.P., and Haskins, M.E. (2007). Gene therapy for mu-copolysaccharidosis. Expert Opin. Biol. Ther. 7, 1333-1345.
53. Ponder, K.P., Wang, B., Wang, P., et al. (2006). Mucopoly-saccharidosis I cats mount a cytotoxic T lymphocyte response after neonatal gene therapy that can be blocked with CTLA4-Ig. Mol. Ther. 14, 5-13.
54. Rucker, M., Fraites, T.J., Jr., Porvasnik, S.L., et al. (2004). Rescue of enzyme deficiency in embryonic diaphragm in a mouse model of metabolic myopathy: Pompe disease. Development 131, 3007-3019.
55. Ruzo, A., Garcia, M., Ribera, A., et al. (2012). Liver production of sulfamidase reverses peripheral and ameliorates CNS pathology in mucopolysaccharidosis IIIA mice. Mol. Ther. 20, 254-266.
56. Sands, M.S., and Davidson, B.L. (2006). Gene therapy for lyso-somal storage diseases. Mol. Ther. 13, 839-849.
57. Sands, M.S., and Haskins, M.E. (2008). CNS-directed gene therapy for lysosomal storage diseases. Acta Paediatr. Suppl. 97, 22-27.
58. Smith, L.J., Martin, J.T., O'Donnell P, et al. (2012). Effect of neonatal gene therapy on lumbar spine disease in mucopo-lysaccharidosis VII dogs. Mol. Genet. Metab. (in press).
59. Sondhi, D., Peterson, D.A., Edelstein, A.M., et al. (2008). Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. Exp. Neurol. 213, 18-27.
60. Stein, C.S., Ghodsi, A., Derksen, T., and Davidson, B.L. (1999). Systemic and central nervous system correction of lysosomal storage in mucopolysaccharidosis type VII mice. J. Virol. 73, 3424-3429.
61. Sun, B., Zhang, H., Bird, A., et al. (2009). Impaired clearance of accumulated lysosomal glycogen in advanced Pompe disease despite high-level vector-mediated transgene expression. J. Gene Med. 11, 913-920.
62. Traas, A.M., Wang, P., Ma, X., et al. (2007). Correction of clinical manifestations of canine mucopolysaccharidosis I with neonatal retroviral vector gene therapy. Mol. Ther. 15, 1423-1431.
63. Vanier, M.T. (2010). Niemann-Pick disease type C. Orphanet J. Rare Dis. 5, 16.
64. Visigalli, I., Delai, S., Politi, L.S., et al. (2010). Gene therapy augments the efficacy of hematopoietic cell transplantation and fully corrects mucopolysaccharidosis type I phenotype in the mouse model. Blood 116, 5130-5139.
65. Wang, D., Zhang, W., Kalfa, T.A., et al. (2009). Reprogramming erythroid cells for lysosomal enzyme production leads to visceral and CNS cross-correction in mice with Hurler syndrome. Proc. Natl. Acad. Sci. U.S.A. 106, 19958-19963.
66. Wang, J., Lozier, J., Johnson, G., et al. (2008). Neutralizing antibodies to therapeutic enzymes: Considerations for testing, prevention and treatment. Nat. Biotechnol. 26, 901-908.
67. Warrington, K.H., Jr., and Herzog, R.W. (2006). Treatment of human disease by adeno-associated viral gene transfer. Hum. Genet. 119, 571-603.
68. Wolf, D.A., Lenander, A.W., Nan, Z., et al. (2011). Direct gene transfer to the CNS prevents emergence of neurologic disease in a murine model of mucopolysaccharidosis type I. Neuro-biol. Dis. 43, 123-133.
69. Worgall, S., Sondhi, D., Hackett, N.R., et al. (2008). Treatment of late infantile neuronal ceroid lipofuscinosis by CNS administration of a serotype 2 adeno-associated virus expressing CLN2 cDNA. Hum. Gene Ther. 19, 463-474.
70. Yoshimitsu, M., Sato, T., Tao, K., et al. (2004). Bioluminescent imaging of a marking transgene and correction of Fabry mice by neonatal injection of recombinant lentiviral vectors. Proc. Natl. Acad. Sci. U.S.A. 101, 16909-16914.
71. Zhang, P., Sun, B., Osada, T., et al. (2012). Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. Hum. Gene Ther. 23, 460-472.
72. Ziegler, R.J., Li, C., Cherry, M., et al. (2002). Correction of the nonlinear dose response improves the viability of adenoviral vectors for gene therapy of Fabry disease. Hum. Gene Ther. 13, 935-945.